GSK plc

NYSE:GSK

Drug Manufacturers - General

Healthcare
$48.58 -2.56%

-$1.34 today

Market cap
$97.53B
Beta
0.29
P/E (TTM)
13.3
EPS (TTM)
$1.45
Dividend yield
3.48%
52W Low $35.45High $61.70

Volume 2.02M

Average 4.07M

News

For GSK plc, read summarized stories built from several publishers and recent headlines with links to the original coverage.

Products & Launches

GSK Wins FDA Accelerated Approval for Lung Cancer Drug Nelkarmi

GSK received accelerated approval from the U.S. Food and Drug Administration for Nelkarmi in advanced ALK-positive lung cancer, clearing the company to launch the medicine in the United States. The drug came to GSK through its acquisition of Nuvalent.

The company is working to build a franchise in lung cancer, which is the leading cause of cancer death, and the approval adds to its oncology portfolio.

GSK reported revenue of 32.67 billion GBP in fiscal 2025. Its next earnings date is scheduled for Feb 3, 2027.

More headlines

Recent coverage that has not been summarized. Links open the publisher's site.